$400M Series C: Insitro Healthcare AI (2023)
Key Facts
- Company
- Insitro
- Sector
- Healthcare AI
- Country
- United States
- Round Type
- Series C
- Investors
- a16z, Canada Pension Plan, ADIA, GV
Funding Round Overview
Insitro announced a Series C round on January 19, 2023 totaling $400,000,000 led by a16z. AI drug discovery startup Insitro raised $400 million Series C. $400M Series C at $2.4B valuation.
Deal Highlights
- Capital involved: $400,000,000.
- Round: Series C.
- Investors: a16z, Canada Pension Plan, ADIA, GV.
Company and Sector Context
Insitro builds in the healthcare ai sector, one of the most active areas in AI investment today. Based in United States, the company is part of a global wave of startups scaling AI into production across regulated and enterprise environments.
How the Capital Helps
Disclosed details include $400M Series C at $2.4B valuation. In healthcare ai, speed to market and access to high-quality talent often determine category leadership.
Competitive Landscape
Funding activity in healthcare ai continues to intensify as incumbents and startups race to ship reliable AI systems. This round signals ongoing investor confidence in differentiated technology and defensible distribution.
Looking Ahead
This funding positions Insitro for continued growth in the healthcare ai landscape. As AI adoption accelerates across industries, deals like this signal where capital and strategic attention are moving next.
News Sources
Frequently Asked Questions
How much did Insitro raise?
Insitro raised $400,000,000 in Series C announced on January 19, 2023.
Who invested in Insitro's Series C?
The investors in Insitro's Series C include a16z, Canada Pension Plan, ADIA, GV.
What sector is Insitro in?
Insitro operates in the Healthcare AI sector and is based in United States.